Key takeaways from the Summer 2020 Life Sciences Industry Outlook:
- Despite the recession, there are signs of strength for life sciences in both public markets and private investment.
- The pandemic has pushed companies to reallocate resources toward COVID-19, causing disruption to the clinical trial pipeline.
- The hot topics of health care and drug pricing reform have taken a backseat as the country deals with the fallout of the pandemic and recession.
Read more at https://rsmus.com/what-we-do/industries/life-sciences/industry-outlook-life-sciences.html